Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Cognitive Impairment and Health Related Quality of Life in Relapsing Remitting Multiple Sclerosis.
[The biological role of sulfatides].
Pharmacoeconomic Aspects of Multiple Sclerosis Treatments in Iran.
All relapsing multiple sclerosis patients should be seen in specialist clinics - NO.
Efficacy of hematopoietic stem cell formultiple sclerosis, an evidence based meta-analysis.
Gut environment-induced intraepithelial autoreactive CD4(+) T cells suppress central nervous system autoimmunity via LAG-3.
Multimodal evoked potentials follow up in multiple sclerosis patients under fingolimod therapy.
Patterns of Use of Tests to Monitor Disease Activity Among Patients With Relapsing Remitting Multiple Sclerosis in the United States and Europe.
A Multimodal Intervention for Patients with Secondary Progressive Multiple Sclerosis: Feasibility and Effect on Fatigue.
25 Hydroxyvitamin D and Cytokines in Multiple Sclerosis.
Phase II Study Showed Ocrelizumab Maintained Significant Reduction in Disease Activity for Multiple Sclerosis Patients for Almost Two Years
Understanding walking activity in multiple sclerosis: step count, walking intensity and uninterrupted walking activity duration related to degree of disability.
Health Care Utilization and Costs of Medicaid Program Services for Patients Diagnosed with Multiple Sclerosis.
Case Report of Lewis and Sumner Syndrome with Bilateral Vagus Nerves Paralysis for 16 Years.
A Study of Ocrelizumab in Comparison with Interferon Beta 1a (Rebif) in Patients with Relapsing Multiple Sclerosis
Evaluation of quality of life in individuals with severe chronic motor disability: A major challenge.
The Efficacy of Functional Electrical Stimulation of the Abdominal Muscles in the Treatment of Chronic Constipation in Patients with Multiple Sclerosis: A Pilot Study.
The Cost Burden of Switching Patients with Relapsing-Remitting Multiple Sclerosis from Glatiramer Acetate To Newly-Approved Disease Modifying Therapies.
Multiple sclerosis patients lacking oligoclonal bands in the cerebrospinal fluid have less global and regional brain atrophy.
Natalizumab-treated patients at high risk for PML persistently excrete JC polyomavirus.
Cost-Utility Analysis (cua) Of First-Line Disease-Modifying Treatments (DMT) Versus Best Supportive Care (Bsc) In Finnish Relapsing-Remitting Multiple Sclerosis (RRMS) Patients.
Evaluation of chronic inflammatory demyelinating polyneuropathy: 3D nerve-sheath signal increased with inked rest-tissue rapid acquisition of relaxation enhancement imaging (3D SHINKEI).
Interferons-beta versus glatiramer acetate for relapsing-remitting multiple sclerosis.
Evaluation of Disability Progression as an Endpoint in Clinical Trials for Relapsing-Remitting Multiple Sclerosis (RRMS): Comparison of the Define and Confirm Studies.
MicroRNAs targeting TGFβ signalling underlie the regulatory T cell defect in multiple sclerosis.

Pages